Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (2358)	6/26/1999 3:35:00 AM
From: Walter Morton	Respond to of 2742

Well my top guesses include a pick that Rudy made several months ago: Cytel Corp. discovers, designs and develops new drugs for the effective treatment of acute and chronic inflammatory diseases, infectious diseases and cancer. CYTL: biz.yahoo.com Genzyme Tissue Repair develops products that will augment or positively modify naturally occurring biological processes involved in tissue repair. GZTR: biz.yahoo.com BioSpecifics Technologies Corp. is engaged in the business of producing and licensing for sale by others a fermentation derived enzyme named Collagenase ABC, as well as the researching and developing of additional products derived from this enzyme. BSTC: biz.yahoo.com (Rudy's Pick) Immunomedics, Inc. is engaged in researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based diagnostics and therapeutics for cancer and infectious diseases. IMMU: biz.yahoo.com Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. AKRN also markets ophthalmic surgical instruments and related products. AKRN: biz.yahoo.com North American Vaccine is engaged in the research, development, production, marketing and sale of vaccines for the prevention of infectious diseases in children and adults. NVX: biz.yahoo.com Corvas International is engaged in the design and development of a new generation of therapeutic agents in the fields of blood clot formation (thrombosis), inflammation, cancer and other diseases. CVAS: biz.yahoo.com ITRC develops therapeutics for the treatment of car-diovascular and pulmonary diseases. ITRC's strategy is to develop and add value to therapeutic products and to enter into collaborations or licensing agreements with corporate partners. ITRC: biz.yahoo.com Reasons for Mergers: synergy growth accelerate growth leverage vertical integration increase product lines, depth, width gain market share gain international exposure gain international market share gain a niche market diversification increase return on investment increase return on assets increase return on equity publicity need for new leadership/management facing bankruptcy under bankruptcy easier than starting a new entity increase efficiency politics/contacts